Skip to main content
SpringerLink
Log in

Vergleich der blutglukosesenkenden Effekte von Tirzepatid und Semaglutid

Comparison of tirzepatide versus semaglutide regarding mean change in glycated hemoglobin levels

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ahrén B, Masmiquel L, Kumar H et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5:341–354

    Article  Google Scholar 

  2. Alicic RZ, Cox EJ, Neumiller JJ et al (2021) Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol 17:227–244

    Article  CAS  Google Scholar 

  3. Aroda VR, Ahmann A, Cariou B et al (2019) Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1–7 trials. Diabetes Metab 45:409–418

    Article  CAS  Google Scholar 

  4. Frías JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385:503–515

    Article  Google Scholar 

  5. Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP‑1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392:2180–2193

    Article  CAS  Google Scholar 

  6. Kalyani RR (2021) Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes. Reply. N Engl J Med 385:671–672

    PubMed  Google Scholar 

  7. Wilding JP, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989. https://doi.org/10.1056/NEJMoa2032183

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Endokrinologie, Nephrologie und Rheumatologie, Liebigstr. 18, 04103, Leipzig, Deutschland

    S. Heinitz

Authors
  1. S. Heinitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Heinitz.

Ethics declarations

Interessenkonflikt

S. Heinitz gibt an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heinitz, S. Vergleich der blutglukosesenkenden Effekte von Tirzepatid und Semaglutid. Diabetologe 18, 205–206 (2022). https://doi.org/10.1007/s11428-022-00861-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-022-00861-0

Search

Navigation